Carregant...

Recent advances in antimultiple myeloma drug development

Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharm Pat Anal
Autors principals: Wang, Nuozhou, Bartlow, Patrick, Ouyang, Qin, Xie, Xiang-Qun
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4465869/
https://ncbi.nlm.nih.gov/pubmed/24998287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/ppa.14.18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!